中国药房2024，Vol.35Issue(14)：1737-1742,6.DOI:10.6039/j.issn.1001-0408.2024.14.11
利拉鲁肽对NAFLD合并T2DM患者心血管代谢和左心室结构及功能的影响
Effects of liraglutide on cardiovascular metabolism,left ventricular structure and function in NAFLD patients with T2DM
摘要
Abstract
OBJECTIVE To observe the effects of liraglutide on cardiovascular metabolism,left ventricular structure and function of non-alcoholic fatty liver disease(NAFLD)patients with type 2 diabetes mellitus(T2DM).METHODS Totally 351 NAFLD patients with T2DM were enrolled retrospectively,who visited the Department of Endocrinology in our hospital from January 2019 to December 2022.They were divided into control group(196 cases)and observation group(155 cases)according to different treatment regimens.The control group received conventional standard treatment,and the observation group was additionally given Liraglutide injection 0.6 mg/d subcutaneously once a day based on the control group,adjusted to 1.2 mg/d after 7 days.Both groups received regular treatment for more than 12 months.The propensity matching method was used to match the two groups of patients at a ratio of 1∶1.The cardiovascular metabolism indexes and cardiac ultrasound parameters were compared,and the correlation between left ventricular structure,function parameters and cardiovascular metabolism indexes was analyzed.RESULTS After propensity score matching,there was no significant difference in baseline clinical data between the two groups(each 155 cases)before treatment(P＞0.05).After 12 months of treatment,the waist circumference,weight,body mass index(BMI),systolic blood pressure(SBP),fasting blood glucose(FBG),glycosylated hemoglobin(HbA1c)and triglyceride(TG)of both groups,as well as the diastolic blood pressure(DBP),total cholesterol(TC),uric acid(UA)and left ventricular mass(LVM)of the observation group,exhibited a significant decrease compared to pre-treatment levels(P＜0.05).The high-density lipoprotein cholesterol(HDL-C),estimated glomerular filtration rate(eGFR),and E/A ratio in both groups,as well as the aspartate aminotransferase(AST)in the control group and the left ventricular ejection fraction(LVEF)in the observation group,were all significantly increased compared with before treatment in the same group(P＜0.05).Moreover,the improvement of the above indicators(except for TG and SBP)in the observation group was generally more significant than those in the control group(P＜0.05).The left ventricular structure and functional parameters(LVM,LVEF,E/A ratio)of the two groups before and after treatment had varying degrees of correlation with the patients'waist circumference,body weight,BMI,SBP,FBG and HbA1c.Moreover,BMI(observation group:β=0.229,P=0.004)and SBP(control group:β=0.240,P=0.004;observation group:β=0.226,P=0.007)were independent influential factors for LVM of the patients.CONCLUSIONS Liraglutide combined with conventional standard treatment can effectively control blood glucose in NAFLD patients with T2DM,reduce waist circumference,body weight and blood pressure,improve blood lipid disorders,and protect their cardiac structure and function.关键词
非酒精性脂肪性肝病/2型糖尿病/利拉鲁肽/心血管疾病风险Key words
non-alcoholic fatty liver disease/type 2 diabetes mellitus/liraglutide/cardiovascular risk分类
医药卫生引用本文复制引用
宋白利,付留俊,常毅娜,袁园,姜宏卫,彭慧芳..利拉鲁肽对NAFLD合并T2DM患者心血管代谢和左心室结构及功能的影响[J].中国药房,2024,35(14):1737-1742,6.基金项目
河南省科技发展计划项目(No.222102310008) （No.222102310008）
